Streetbeat News

Price Targets

LOGI

Barclays analyst George Kelly maintains an Overweight rating on Logitech International (NASDAQ:LOGI) and raises the price target from $71 to $81.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 26, 2023 | 10:14 am

CSGP

Needham analyst Mayank Tandon maintains a 'Buy' rating on CoStar Gr (NASDAQ:CSGP) and raises the price target from $90 to $100.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 10:14 am

MSCI

Barclays analyst Manav Patnaik maintains an Overweight rating on MSCI (NYSE:MSCI) and raises the price target from $600 to $650.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 26, 2023 | 10:13 am

SPOT

Barclays analyst Mario Lu maintains an Overweight rating on Spotify Technology (NYSE:SPOT) and raises the price target from $180 to $182.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 26, 2023 | 10:12 am

KPTI

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Karyopharm Therapeutics (NASDAQ:KPTI) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 10:12 am

CCK

Barclays analyst Michael Leithead has maintained an Overweight rating on Crown Holdings (NYSE:CCK) and raised the price target from $95 to $110.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 26, 2023 | 10:11 am

GOSS

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Gossamer Bio (NASDAQ:GOSS) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 10:10 am

TARS

HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $44 to $50.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 10:10 am

SHW

Barclays analyst Michael Leithead maintains an Equal-Weight rating on Sherwin-Williams (NYSE:SHW) and raises the price target from $240 to $285.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 26, 2023 | 10:09 am

BIIB

Needham analyst Ami Fadia maintains a Buy rating on Biogen (NASDAQ:BIIB) and raises the price target from $320 to $323.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 10:08 am